FORMULATION OF L-ORNITHINE PHENYLACETATE
Some embodiments of the present application are directed to oral formulations of L- ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammone...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Laurene, WANG Stanley, BUKOFZER Linda S. GRAIS |
| description | Some embodiments of the present application are directed to oral formulations of L- ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y métodos para usar las mismas. Estas formulaciones orales ofrecen ruta alternativa de administración que la administración intravenosa estándar de fenilacetato de Lornitina para tratar hiperamonemia en pacientes que tienen enfermedades y trastornos agudos y crónicos del hígado, por ejemplo, falla hepática aguda, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MX2018005088A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MX2018005088A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MX2018005088A3</originalsourceid><addsrcrecordid>eNrjZNBw8w_yDfVxDPH091Pwd1Pw0fUP8vMM8fD0c1UI8HD1i_RxdHYNcQxx5WFgTUvMKU7lhdLcDEpuriHOHrqpBfnxqcUFicmpeakl8b4RRgaGFgYGpgYWFo7GRCkCAGdsJM4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FORMULATION OF L-ORNITHINE PHENYLACETATE</title><source>esp@cenet</source><creator>Laurene, WANG ; Stanley, BUKOFZER ; Linda S. GRAIS</creator><creatorcontrib>Laurene, WANG ; Stanley, BUKOFZER ; Linda S. GRAIS</creatorcontrib><description>Some embodiments of the present application are directed to oral formulations of L- ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y métodos para usar las mismas. Estas formulaciones orales ofrecen ruta alternativa de administración que la administración intravenosa estándar de fenilacetato de Lornitina para tratar hiperamonemia en pacientes que tienen enfermedades y trastornos agudos y crónicos del hígado, por ejemplo, falla hepática aguda, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea.</description><language>eng ; spa</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190516&DB=EPODOC&CC=MX&NR=2018005088A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190516&DB=EPODOC&CC=MX&NR=2018005088A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Laurene, WANG</creatorcontrib><creatorcontrib>Stanley, BUKOFZER</creatorcontrib><creatorcontrib>Linda S. GRAIS</creatorcontrib><title>FORMULATION OF L-ORNITHINE PHENYLACETATE</title><description>Some embodiments of the present application are directed to oral formulations of L- ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y métodos para usar las mismas. Estas formulaciones orales ofrecen ruta alternativa de administración que la administración intravenosa estándar de fenilacetato de Lornitina para tratar hiperamonemia en pacientes que tienen enfermedades y trastornos agudos y crónicos del hígado, por ejemplo, falla hepática aguda, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNBw8w_yDfVxDPH091Pwd1Pw0fUP8vMM8fD0c1UI8HD1i_RxdHYNcQxx5WFgTUvMKU7lhdLcDEpuriHOHrqpBfnxqcUFicmpeakl8b4RRgaGFgYGpgYWFo7GRCkCAGdsJM4</recordid><startdate>20190516</startdate><enddate>20190516</enddate><creator>Laurene, WANG</creator><creator>Stanley, BUKOFZER</creator><creator>Linda S. GRAIS</creator><scope>EVB</scope></search><sort><creationdate>20190516</creationdate><title>FORMULATION OF L-ORNITHINE PHENYLACETATE</title><author>Laurene, WANG ; Stanley, BUKOFZER ; Linda S. GRAIS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MX2018005088A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2019</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Laurene, WANG</creatorcontrib><creatorcontrib>Stanley, BUKOFZER</creatorcontrib><creatorcontrib>Linda S. GRAIS</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Laurene, WANG</au><au>Stanley, BUKOFZER</au><au>Linda S. GRAIS</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FORMULATION OF L-ORNITHINE PHENYLACETATE</title><date>2019-05-16</date><risdate>2019</risdate><abstract>Some embodiments of the present application are directed to oral formulations of L- ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y métodos para usar las mismas. Estas formulaciones orales ofrecen ruta alternativa de administración que la administración intravenosa estándar de fenilacetato de Lornitina para tratar hiperamonemia en pacientes que tienen enfermedades y trastornos agudos y crónicos del hígado, por ejemplo, falla hepática aguda, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; spa |
| recordid | cdi_epo_espacenet_MX2018005088A |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | FORMULATION OF L-ORNITHINE PHENYLACETATE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A26%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Laurene,%20WANG&rft.date=2019-05-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMX2018005088A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |